SDGR

Schrodinger Inc

Apr 08 • 04:00PM ET

11.50

+0.11 0.97 %

Healthcare • Health Information Services • USA • NASD

Peers: REGN GILD BIIB VRTX BMRN NBIX INCY EXEL SAGE IONS

| Held by: IJR VTI ARKG VB IWM VBK VXF SPSM IJT IWO

Index	RUT	P/E	-	EPS (ttm)	-1.41	Insider Own	14.87%	Shs Outstand	64.52M	Perf Week	1.23%
Market Cap	848.99M	Forward P/E	-	EPS next Y	-1.48	Insider Trans	-0.15%	Shs Float	62.85M	Perf Month	-11.20%
Enterprise Value	555.89M	PEG	-	EPS next Q	-0.64	Inst Own	95.30%	Short Float	18.01%	Perf Quarter	-38.80%
Income	-103.27M	P/S	3.32	EPS this Y	-50.41%	Inst Trans	0.93%	Short Ratio	8.38	Perf Half Y	-45.98%
Sales	255.87M	P/B	2.33	EPS next Y	30.31%	ROA	-13.33%	Short Interest	11.32M	Perf YTD	-35.68%
Book/sh	4.94	P/C	2.11	EPS next 5Y	34.67%	ROE	-26.29%	52W High	27.63 -58.38%	Perf Year	-36.00%
Cash/sh	5.45	P/FCF	68.14	EPS past 3/5Y	12.46% -28.10%	ROIC	-22.60%	52W Low	10.94 5.07%	Perf 3Y	-57.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	12.24% 18.81%	Gross Margin	55.74%	Volatility	4.17% 4.38%	Perf 5Y	-85.05%
Dividend TTM	-	EV/Sales	2.17	EPS Y/Y TTM	45.23%	Oper. Margin	-65.23%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	23.29%	Profit Margin	-40.36%	RSI (14)	42.22	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	179.96%	SMA20	-2.56%	Beta	1.64	Target Price	22.00
Payout	-	Debt/Eq	0.30	Sales Q/Q	-1.23%	SMA50	-6.97%	Rel Volume	1.02	Prev Close	11.39
Employees	850	LT Debt/Eq	0.25	Earnings	Feb 25 AMC	SMA200	-34.71%	Avg Volume	1.35M	Price	11.50
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	344.17% 4.11%	Trades		Volume	1,380,781	Change	0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$24
Sep-30-25	Initiated	Goldman	Neutral	$19
Aug-15-25	Downgrade	Citigroup	Buy → Neutral	$20
Aug-14-25	Initiated	Barclays	Overweight	$25
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$28
Jul-02-24	Initiated	Leerink Partners	Outperform	$29
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$38
May-05-23	Resumed	Piper Sandler	Overweight	$60
Dec-19-22	Initiated	Goldman	Neutral	$23
Mar-01-22	Initiated	Citigroup	Buy	$55
Nov-19-21	Initiated	Piper Sandler	Overweight	$87
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$82 → $49
Nov-11-21	Downgrade	BofA Securities	Buy → Neutral	$80 → $52
Oct-13-21	Initiated	Berenberg	Buy	$91
Sep-01-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$82
May-25-21	Initiated	Craig Hallum	Buy	$85
Nov-23-20	Upgrade	BofA Securities	Neutral → Buy	$74
Oct-12-20	Upgrade	Jefferies	Hold → Buy
Mar-02-20	Initiated	Morgan Stanley	Equal-Weight	$43
Mar-02-20	Initiated	Jefferies	Hold	$42

Show Previous Ratings

Mar-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-02-26 12:13PM	Can AI Acceleration and R&D Strength Drive VEEV Ahead of Q4 Earnings? (Zacks)
02:57AM	Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth (Insider Monkey)
Feb-26-26 08:30AM	Schrödinger, Inc. Q4 2025 Earnings Call Summary (Moby) +8.14%
03:08AM	Schrodinger Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Loading…
12:03AM	Schrodinger Inc (SDGR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Transition ... (GuruFocus.com)
Feb-25-26 04:05PM	Schrdinger Reports Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
10:00AM	Nvidia Earnings Slam Into Market With No Patience for AI Hiccups (Bloomberg)
Feb-24-26 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
Feb-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-12-26 05:30PM	10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -5.59%
Feb-11-26 08:30AM	Schrdinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25 (Business Wire) -12.11%
Feb-03-26 03:38AM	TruBridge (TBRG) Surges 5.6%: Is This an Indication of Further Gains? (Zacks) -5.04%
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
Jan-12-26 08:30AM	Schrodinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities (Business Wire)
07:00AM	Loading…
Jan-09-26 07:00AM	Schrodinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign (Business Wire)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-02-26 12:10PM	CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus (Zacks)
Dec-31-25 10:30AM	KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic (Zacks)
Dec-23-25 12:35PM	FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform (Zacks)
09:48AM	Do Options Traders Know Something About Schrodinger Stock We Don't? (Zacks)
Dec-22-25 09:53AM	BofA Upgrades Schrodinger (SDGR) to Buy After Strategic Pivot to Software (Insider Monkey) +9.80%
Dec-20-25 06:35AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Dec-17-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-12-25 09:55AM	Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-10-25 09:55AM	Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-07-25 02:26AM	Schrodinger (SDGR) and Copernic Catalysts Surpass the Final Technical Milestone for Neptune (Insider Monkey)
Nov-06-25 08:30AM	Schrodinger to Present at Jefferies London Healthcare Conference (Business Wire) -5.67%
12:06AM	Schrodinger Inc (SDGR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... (GuruFocus.com)
06:40PM	Loading…
Nov-05-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Third Quarter 2025 Financial Results (Business Wire)
07:15AM	Meta Slumps on AI Spending, Echoing 2022 Metaverse Rout (Bloomberg)
Nov-04-25 05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:58AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q3 2025 Result (GuruFocus.com)
Oct-30-25 07:30AM	Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrodinger (Business Wire)
Oct-22-25 08:30AM	Schrodinger to Announce Third Quarter 2025 Financial Results on November 5 (Business Wire)
Oct-21-25 07:05AM	Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength? (Zacks) -5.05%
Oct-15-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
Sep-18-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-25 09:55AM	Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:30AM	Schrodinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-15-25 04:30PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-14-25 07:00AM	Schrödinger Announces Discontinuation of SGR-2921 Program (Business Wire)
07:00AM	Schrodinger Announces Discontinuation of SGR-2921 Program (Business Wire)
Aug-06-25 06:30PM	Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 06:05PM	Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates (Zacks)
09:52AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result (GuruFocus.com)
Aug-01-25 12:08PM	Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition? (Zacks)
Jul-25-25 08:30AM	Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
08:30AM	Schrodinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-24-25 10:00AM	Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
10:00AM	Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 08:00AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-17-25 08:00AM	Ajax Therapeutics and Schrdinger Expand Research Collaboration to Include Additional JAK Target (Business Wire)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage on Schrodinger (SDGR) Stock (Insider Monkey)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-04-25 09:45AM	Meta upgraded, PNC Financial downgraded: Wall Streets top analyst calls (TipRanks)
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
08:35AM	MS initiates coverage on AI Biotechs, flags key pipeline catalysts (Investing.com)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jun-27-25 08:00AM	Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia (Business Wire)
08:00AM	Schrodinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenstrom Macroglobulinemia (Business Wire)
Jun-17-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-25 07:00AM	Schrdinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress (Business Wire) -14.44%
May-29-25 05:00PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
05:00PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
08:00AM	Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
08:00AM	Schrodinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
May-27-25 10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks)
May-23-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-22-25 08:30AM	Schrödinger to Present at Jefferies Global Healthcare Conference (Business Wire)
08:30AM	Schrodinger to Present at Jefferies Global Healthcare Conference (Business Wire)
May-21-25 04:26AM	Leadership Transition at Schrodinger: Richie Jain Named CFO (Insider Monkey)
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive) -8.62%
06:30AM	Schrödinger Announces CFO Appointment (Business Wire)
06:30AM	Schrodinger Announces CFO Appointment (Business Wire)
May-14-25 09:30AM	Schrdinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma (Business Wire)
May-08-25 07:42AM	Q1 2025 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
May-07-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Schrodinger projects strong 2025 revenue growth with $45M-$50M in drug discovery (Seeking Alpha)
05:59PM	Schrodinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:05PM	Schrdinger Reports Strong First Quarter 2025 Financial Results (Business Wire)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.31%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
08:30AM	Schrdinger to Present at BofA Securities 2025 Healthcare Conference (Business Wire)
May-02-25 08:10AM	Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-28-25 08:00AM	Schrdinger Presents New Preclinical Data at AACR Annual Meeting (Business Wire)
Apr-23-25 10:27AM	Schrodinger, Inc. (SDGR): Among Top Stocks in Bill Gates' Portfolio with Huge Upside Potential (Insider Monkey)
08:30AM	Schrdinger to Announce First Quarter 2025 Financial Results on May 7 (Business Wire)

Schrodinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herman Jenny	CAO	Mar 05 '26	Sale	12.85	775	9,956	35,412	Mar 06 05:29 PM
Herman Jenny	CAO	Mar 06 '26	Sale	12.84	608	7,808	34,804	Mar 06 05:29 PM
Jain Rachit	EVP & CFO	Mar 05 '26	Sale	12.90	1,631	21,033	52,596	Mar 06 05:29 PM
Tran Yvonne	EVP, CLO & CPO	Mar 05 '26	Sale	12.89	1,094	14,107	52,683	Mar 06 05:28 PM
Farid Ramy	President & CEO	Mar 05 '26	Sale	12.91	3,661	47,249	330,824	Mar 06 05:28 PM
Akinsanya Karen	See Remarks	Mar 05 '26	Sale	12.90	1,366	17,625	69,956	Mar 06 05:27 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Mar 05 '26	Sale	12.90	1,222	15,761	89,241	Mar 06 05:26 PM
Abel Robert Lorne	See Remarks	Mar 04 '26	Sale	12.81	1,300	16,653	55,897	Mar 06 05:26 PM
Herman Jenny	Officer	Mar 06 '26	Proposed Sale	12.84	608	7,808		Mar 06 03:18 PM
Lorton Kenneth Patrick	Officer	Mar 05 '26	Proposed Sale	12.90	1,222	15,762		Mar 05 03:27 PM
Tran Yvonne	Officer	Mar 05 '26	Proposed Sale	12.89	1,094	14,107		Mar 05 03:16 PM
Herman Jenny	Officer	Mar 05 '26	Proposed Sale	12.85	775	9,955		Mar 05 03:16 PM
Farid Ramy	Officer	Mar 05 '26	Proposed Sale	12.91	3,661	47,248		Mar 05 03:14 PM
Jain Rachit	Officer	Mar 05 '26	Proposed Sale	12.90	1,631	21,034		Mar 05 03:07 PM
Akinsanya Karen	Officer	Mar 05 '26	Proposed Sale	12.90	1,366	17,625		Mar 05 03:05 PM
Robert Abel	Officer	Mar 04 '26	Proposed Sale	12.73	1,300	16,549		Mar 04 10:21 AM
Farid Ramy	Officer	Mar 02 '26	Proposed Sale	11.90	5,560	66,151		Mar 02 05:06 PM
Akinsanya Karen	Officer	Mar 02 '26	Proposed Sale	11.99	2,206	26,454		Mar 02 04:35 PM
Tran Yvonne	EVP, CLO & CPO	Feb 10 '26	Sale	13.80	776	10,705	22,859	Feb 12 04:23 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Feb 10 '26	Sale	13.73	925	12,704	52,651	Feb 12 04:22 PM
Herman Jenny	CAO	Feb 10 '26	Sale	13.79	752	10,370	26,597	Feb 12 04:21 PM
Abel Robert Lorne	See Remarks	Feb 09 '26	Sale	13.51	1,230	16,617	19,385	Feb 11 06:00 PM
Herman Jenny	Officer	Feb 10 '26	Proposed Sale	13.79	752	10,370		Feb 10 03:40 PM
Lorton Kenneth Patrick	Officer	Feb 10 '26	Proposed Sale	13.73	925	12,704		Feb 10 03:35 PM
Tran Yvonne	Officer	Feb 10 '26	Proposed Sale	13.80	776	10,705		Feb 10 03:29 PM
Robert Abel	Officer	Feb 09 '26	Proposed Sale	13.43	1,230	16,519		Feb 09 03:21 PM
Dugan Margaret	Chief Medical Officer	Oct 16 '25	Sale	21.07	1,395	29,387	24,574	Oct 17 04:28 PM
Dugan Margaret	Officer	Oct 16 '25	Proposed Sale	21.07	1,395	29,387		Oct 16 03:16 PM
Akinsanya Karen	President of R&D, Therapeutics	Apr 14 '25	Option Exercise	3.16	16,723	52,845	32,348	Apr 15 04:31 PM
Akinsanya Karen	President of R&D, Therapeutics	Apr 14 '25	Sale	25.09	16,723	419,570	15,625	Apr 15 04:31 PM
Karen Akinsanya	Officer	Apr 14 '25	Proposed Sale	24.49	16,723	409,546		Apr 14 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SDGR

Schrodinger Inc

Upgrade your Finviz experience